Crossmark

Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria

Crossref DOI link: https://doi.org/10.1186/s12885-018-4821-8

Published Online: 2018-09-26

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hoyer, Juliane http://orcid.org/0000-0002-9368-0767
Vasileiou, Georgia

Uebe, Steffen

Wunderle, Marius

Kraus, Cornelia

Fasching, Peter A.

Thiel, Christian T.

Hartmann, Arndt

Beckmann, Matthias W.

Lux, Michael P.

Reis, André
License Information

Text and Data Mining valid from 2018-09-26
More Information

Article History

Received: 20 October 2017

Accepted: 14 September 2018

First Online: 26 September 2018

Ethics approval

: All procedures were in accordance with the ethical standards of the FAU Erlangen-Nürnberg and the Helsinki Declaration. All analyses beyond diagnostic procedures were part of the study “Aufklärung genetischer Ursachen für familiären Brust- und Eierstockkrebs” approved by the ethics committee of the Friedrich-Alexander-Universität Erlangen-Nürnberg (Ethik-Kommission der FAU, No. 46_15 B). Written informed consent for diagnostic procedure (§3 Nr. 7 GenDG) in accordance with the Gendiagnostik-Kommission (GEKO,ExternalRef removed) of the Bundesministerium für Gesundheit of the German Government was obtained from all participants in this study.

: Not applicable.

: Peter A. Fasching received honoraria from Novartis, Pfizer, Roche and Celgene. Peter A. Fasching’s institution received research funding from Novartis. All other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below